Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 60 to 85

NAD supplementation to improve brain vascular health in older adults

Official title: Effects of NAD Restoration on Neurovascular Coupling in Community Dwelling Older Adults

Run by University of Oklahoma · NCT05483465 · Data updated 2026-11-12

This study is testing if a vitamin called Nicotinamide Riboside can help improve brain health and memory in older adults by boosting a key molecule in the brain.

More Aging trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages60 Years to 85 Years
SexAll
Enrollment214 (estimated)
SponsorUniversity of Oklahoma
Academic / other
Locations1 site (Oklahoma City, Oklahoma)
StatusRecruiting
StartedMay 3, 2023
Main results expectedJune 2027
Study endsDecember 2027
Registry record updatedApril 1, 2026
Trial IDNCT05483465 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are community-dwelling older adults aged 60 to 85 who can provide informed consent and have adequate cognitive function.

Probably not a fit

Patients with active CNS diseases, major psychiatric disorders, or significant kidney or liver dysfunction may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests whether Nicotinamide Riboside (NR), a form of Vitamin B3, can enhance brain health and memory in older adults by restoring levels of Nicotinamide Adenine Dinucleotide (NAD). Participants aged 60 to 85 will receive either NR or a placebo for 8 weeks, with assessments focused on neurovascular coupling and endothelial function. The study aims to determine if daily NR supplementation can lead to significant improvements in brain vascular health.

Why it matters

Potential benefit: If successful, this could lead to new strategies for improving brain health and memory in aging populations.

How similar studies have gone: Other studies have shown promising results with NAD supplementation, but this specific approach in older adults is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥60 and ≤85 years of age
* Adequate hearing and visual acuity to participate in the examinations
* Ability to read and write in English
* Competence to provide informed consent.
* Mini-Mental State Exam score ≥24

Exclusion Criteria:

* Vision or hearing impairment that would impair the ability to complete study assessments
* Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer
* Cerebrovascular accident other than TIA within 60 days prior to Visit 0
* Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse
* Abnormal kidney function (creatinine \>2mg/dL or EGFR \<30mL/min) by most recent labs within 6 months prior to Visit 0
* Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by most recent labs within 6 months prior to Visit 0
* Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamide mononucleotide) within 4 weeks prior to randomization.
* Any other medical condition which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol

Where it's running

  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.